Gossamer Bio的短期利息下跌了12.8%,其股票超过了分析师的预期,评级为“Buy”。 Gossamer Bio's short interest fell 12.8%, and its stock surpassed analyst expectations, with a "Buy" rating.

Gossamer Bio是一家生物制药公司,12月的短期利息下降12.8%,共计6 120 000股。 Gossamer Bio, a biopharmaceutical company, saw short interest drop by 12.8% in December, totaling 6,120,000 shares. 机构投资者拥有其81.23%的股票。 Institutional investors own 81.23% of its stock. 该公司报告了积极的金融活动,股票交易额为0.96美元,每股收入(0.14美元),打人分析师估计。 The company has reported positive financial activity, with shares trading at $0.96 and earnings per share of ($0.14), beating analyst estimates. Gossamer Bio正在开发肺动脉高血压治疗的Seralutinib, 获得一致的“Buy”评分, 目标价格为9. 20美元。 Gossamer Bio is developing seralutinib for pulmonary arterial hypertension treatment, with a consensus "Buy" rating and a target price of $9.20.